Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
|
摘要
The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition(dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases(inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract(e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.
The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition(dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases(inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract(e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.
The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition(dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases(inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract(e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.
引文
1 Bckhed F,Ley RE,Sonnenburg JL,Peterson DA,Gordon JI.Host-bacterial mutualism in the human intestine.Science2005;307:1915-1920[PMID:15790844 DOI:10.1126/science.1104816]
2 Gill SR,Pop M,Deboy RT,Eckburg PB,Turnbaugh PJ,Samuel BS,Gordon JI,Relman DA,Fraser-Liggett CM,Nelson KE.Metagenomic analysis of the human distal gut microbiome.Science 2006;312:1355-1359[PMID:16741115 DOI:10 .1126/science.1124234]
3 Kim BS,Jeon YS,Chun J.Current status and future promise of the human microbiome.Pediatr Gastroenterol Hepatol Nutr 2013;16:71-79[PMID:24010110 DOI:10.5223/pghn.2013.16.2.71]
4 Eckburg PB,Bik EM,Bernstein CN,Purdom E,Dethlefsen L,Sargent M,Gill SR,Nelson KE,Relman DA.Diversity of the human intestinal microbial flora.Science 2005;308:1635-1638[PMID:15831718 DOI:10.1126/science.1110591]
5 Arumugam M,Raes J,Pelletier E,Le Paslier D,Yamada T,Mende DR,Fernandes GR,Tap J,Bruls T,Batto JM,Bertalan M,Borruel N,Casellas F,Fernandez L,Gautier L,Hansen T,Hattori M,Hayashi T,Kleerebezem M,Kurokawa K,Leclerc M,Levenez F,Manichanh C,Nielsen HB,Nielsen T,Pons N,Poulain J,Qin J,Sicheritz-Ponten T,Tims S,Torrents D,Ugarte E,Zoetendal EG,Wang J,Guarner F,Pedersen O,de Vos WM,Brunak S,DoréJ,Antolín M,Artiguenave F,Blottiere HM,Almeida M,Brechot C,Cara C,Chervaux C,Cultrone A,Delorme C,Denariaz G,Dervyn R,Foerstner KU,Friss C,van de Guchte M,Guedon E,Haimet F,HuberW,van Hylckama-Vlieg J,Jamet A,Juste C,Kaci G,Knol J,Lakhdari O,Layec S,Le Roux K,Maguin E,Mérieux A,Melo Minardi R,M’rini C,Muller J,Oozeer R,Parkhill J,Renault P,Rescigno M,Sanchez N,Sunagawa S,Torrejon A,Turner K,Vandemeulebrouck G,Varela E,Winogradsky Y,Zeller G,Weissenbach J,Ehrlich SD,Bork P.Enterotypes of the human gut microbiome.Nature 2011;473:174-180[PMID:21508958DOI:10.1038/nature09944]
6 Lozupone CA,Stombaugh JI,Gordon JI,Jansson JK,Knight R.Diversity,stability and resilience of the human gut microbiota.Nature 2012;489:220-230[PMID:22972295 DOI:10 .1038/nature11550]
7 Arboleya S,Solís G,Fernández N,de los Reyes-Gavilán CG,Gueimonde M.Facultative to strict anaerobes ratio in the preterm infant microbiota:a target for intervention?Gut Microbes 2012;3:583-588[PMID:22922559 DOI:10.4161/gmic.21942]
8 Claesson MJ,Cusack S,O’Sullivan O,Greene-Diniz R,de Weerd H,Flannery E,Marchesi JR,Falush D,Dinan T,Fitzgerald G,Stanton C,van Sinderen D,O’Connor M,Harnedy N,O’Connor K,Henry C,O’Mahony D,Fitzgerald AP,Shanahan F,Twomey C,Hill C,Ross RP,O’Toole PW.Composition,variability,and temporal stability of the intestinal microbiota of the elderly.Proc Natl Acad Sci USA2011;108 Suppl 1:4586-4591[PMID:20571116 DOI:10.1073/pnas.1000097107]
9 Salazar N,López P,Valdés L,Margolles A,Suárez A,Patterson AM,Cuervo A,de los Reyes-Gavilán CG,Ruas-Madiedo P,González S,Gueimonde M.Microbial targets for the development of functional foods accordingly with nutritional and immune parameters altered in the elderly.J Am Coll Nutr 2013;32:399-406[DOI:10.1080/07315724.2013.827047]
10 Cani PD,Everard A,Duparc T.Gut microbiota,enteroendocrine functions and metabolism.Curr Opin Pharmacol 2013;13:935-940[PMID:24075718 DOI:10.1016/j.coph.2013.09.008]
11 Reigstad CS,Kashyap PC.Beyond phylotyping:understanding the impact of gut microbiota on host biology.Neurogastroenterol Motil 2013;25:358-372[PMID:23594242 DOI:10 .1111/nmo.12134]
12 Flint HJ,Scott KP,Louis P,Duncan SH.The role of the gut microbiota in nutrition and health.Nat Rev Gastroenterol Hepatol 2012;9:577-589[PMID:22945443 DOI:10.1038/nrgastro.2012.156]
13 Sjgren YM,Tomicic S,Lundberg A,Bttcher MF,Bjrkstén B,Sverremark-Ekstrm E,Jenmalm MC.Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses.Clin Exp Allergy 2009;39:1842-1851[PMID:19735274 DOI:10.1111/j.1365-2222.2009.03326.x]
14 Martin R,Nauta AJ,Ben Amor K,Knippels LM,Knol J,Garssen J.Early life:gut microbiota and immune development in infancy.Benef Microbes 2010;1:367-382[PMID:21831776 DOI:10.3920/BM2010.0027]
15 Hsiao EY,McBride SW,Hsien S,Sharon G,Hyde ER,McCue T,Codelli JA,Chow J,Reisman SE,Petrosino JF,Patterson PH,Mazmanian SK.Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders.Cell 2013;155:1451-1463[PMID:24315484DOI:10.1016/j.cell.2013.11.024]
16 Wu GD,Chen J,Hoffmann C,Bittinger K,Chen YY,Keilbaugh SA,Bewtra M,Knights D,Walters WA,Knight R,Sinha R,Gilroy E,Gupta K,Baldassano R,Nessel L,Li H,Bushman FD,Lewis JD.Linking long-term dietary patterns with gut microbial enterotypes.Science 2011;334:105-108[PMID:21885731 DOI:10.1126/science.1208344]
17 Yatsunenko T,Rey FE,Manary MJ,Trehan I,DominguezBello MG,Contreras M,Magris M,Hidalgo G,Baldassano RN,Anokhin AP,Heath AC,Warner B,Reeder J,Kuczynski J,Caporaso JG,Lozupone CA,Lauber C,Clemente JC,KnightsD,Knight R,Gordon JI.Human gut microbiome viewed across age and geography.Nature 2012;486:222-227[PMID:22699611 DOI:10.1038/nature11053]
18 Arboleya S,Ang L,Margolles A,Yiyuan L,Dongya Z,Liang X,Solís G,Fernández N,de Los Reyes-Gavilán CG,Gueimonde M.Deep 16S rRNA metagenomics and quantitative PCR analyses of the premature infant fecal microbiota.Anaerobe 2012;18:378-380[PMID:22579986 DOI:10.1016/j.anaerobe.2012.04.013]
19 Pérez-Cobas AE,Artacho A,Knecht H,Ferrús ML,Friedrichs A,Ott SJ,Moya A,Latorre A,Gosalbes MJ.Differential effects of antibiotic therapy on the structure and function of human gut microbiota.PLoS One 2013;8:e80201[PMID:24282523 DOI:10.1371/journal.pone.0080201]
20 Aziz Q,DoréJ,Emmanuel A,Guarner F,Quigley EM.Gut microbiota and gastrointestinal health:current concepts and future directions.Neurogastroenterol Motil 2013;25:4-15[PMID:23279728 DOI:10.1111/nmo.12046]
21 Wu GD,Lewis JD.Analysis of the human gut microbiome and association with disease.Clin Gastroenterol Hepatol 2013;11 :774-777[PMID:23643636 DOI:10.1016/j.cgh.2013.03.038]
22 Shanahan F,Quigley EM.Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies.Gastroenterology 2014;146:1554-1563[PMID:24486051 DOI:10 .1053/j.gastro.2014.01.050]
23 Fraher MH,O’Toole PW,Quigley EM.Techniques used to characterize the gut microbiota:a guide for the clinician.Nat Rev Gastroenterol Hepatol 2012;9:312-322[PMID:22450307DOI:10.1038/nrgastro.2012.44]
24 van Nood E,Vrieze A,Nieuwdorp M,Fuentes S,Zoetendal EG,de Vos WM,Visser CE,Kuijper EJ,Bartelsman JF,Tijssen JG,Speelman P,Dijkgraaf MG,Keller JJ.Duodenal infusion of donor feces for recurrent Clostridium difficile.N Engl J Med 2013;368:407-415[PMID:23323867 DOI:10.1056/NEJMoa1205037]
25 Borody TJ,Khoruts A.Fecal microbiota transplantation and emerging applications.Nat Rev Gastroenterol Hepatol 2012;9:88 -96[PMID:22183182 DOI:10.1038/nrgastro.2011.244]
26 Smits LP,Bouter KE,de Vos WM,Borody TJ,Nieuwdorp M.Therapeutic potential of fecal microbiota transplantation.Gastroenterology 2013;145:946-953[PMID:24018052 DOI:10 .1053/j.gastro.2013.08.058]
27 Sanders ME,Guarner F,Guerrant R,Holt PR,Quigley EM,Sartor RB,Sherman PM,Mayer EA.An update on the use and investigation of probiotics in health and disease.Gut 2013;62:787-796[PMID:23474420 DOI:10.1136/gutjnl-2012-302504]
28 Borody TJ,Brandt LJ,Paramsothy S.Therapeutic faecal microbiota transplantation:current status and future developments.Curr Opin Gastroenterol 2014;30:97-105[PMID:24257037 DOI:10.1097/MOG.0000000000000027]
29 Manichanh C,Borruel N,Casellas F,Guarner F.The gut microbiota in IBD.Nat Rev Gastroenterol Hepatol 2012;9:599-608[PMID:22907164 DOI:10.1038/nrgastro.2012.152]
30 Knights D,Lassen KG,Xavier RJ.Advances in inflammatory bowel disease pathogenesis:linking host genetics and the microbiome.Gut 2013;62:1505-1510[PMID:24037875 DOI:10 .1136/gutjnl-2012-303954]
31 Guarner F.What is the role of the enteric commensal flora in IBD?Inflamm Bowel Dis 2008;14 Suppl 2:S83-S84[PMID:18816773 DOI:10.1002/ibd.20548]
32 Kostic AD,Xavier RJ,Gevers D.The microbiome in inflammatory bowel disease:current status and the future ahead.Gastroenterology 2014;146:1489-1499[PMID:24560869 DOI:10 .1053/j.gastro.2014.02.009]
33 Ott SJ,Musfeldt M,Wenderoth DF,Hampe J,Brant O,Flsch UR,Timmis KN,Schreiber S.Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.Gut 2004;53:685 -693[PMID:15082587]
34 Martinez C,Antolin M,Santos J,Torrejon A,Casellas F,Borruel N,Guarner F,Malagelada JR.Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission.Am J Gastroenterol 2008;103:643-648[PMID:18341488DOI:10.1111/j.1572-0241.2007.01592.x]
35 Chassaing B,Darfeuille-Michaud A.The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases.Gastroenterology 2011;140:1720-1728[PMID:21530738 DOI:10.1053/j.gastro.2011.01.054]
36 Rowan F,Docherty NG,Murphy M,Murphy B,Calvin Coffey J,O’Connell PR.Desulfovibrio bacterial species are increased in ulcerative colitis.Dis Colon Rectum2010;53:1530-1536[PMID:20940602 DOI:10.1007/DCR.0b013e3181f1e620]
37 Morgan XC,Tickle TL,Sokol H,Gevers D,Devaney KL,Ward DV,Reyes JA,Shah SA,LeLeiko N,Snapper SB,Bousvaros A,Korzenik J,Sands BE,Xavier RJ,Huttenhower C.Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.Genome Biol 2012;13:R79[PMID:23013615 DOI:10.1186/gb-2012-13-9-r79]
38 Sokol H,Pigneur B,Watterlot L,Lakhdari O,BermúdezHumarán LG,Gratadoux JJ,Blugeon S,Bridonneau C,Furet JP,Corthier G,Grangette C,Vasquez N,Pochart P,Trugnan G,Thomas G,Blottière HM,DoréJ,Marteau P,Seksik P,Langella P.Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.Proc Natl Acad Sci USA2008;105:16731-16736[PMID:18936492 DOI:10.1073/pnas.0804812105]
39 Willing B,Halfvarson J,Dicksved J,Rosenquist M,Jrnerot G,Engstrand L,Tysk C,Jansson JK.Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease.Inflamm Bowel Dis 2009;15 :653-660[PMID:19023901 DOI:10.1002/ibd.20783]
40 Darfeuille-Michaud A,Boudeau J,Bulois P,Neut C,Glasser AL,Barnich N,Bringer MA,Swidsinski A,Beaugerie L,Colombel JF.High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease.Gastroenterology 2004;127:412-421[PMID:15300573]
41 Erickson AR,Cantarel BL,Lamendella R,Darzi Y,Mongodin EF,Pan C,Shah M,Halfvarson J,Tysk C,Henrissat B,Raes J,Verberkmoes NC,Fraser CM,Hettich RL,Jansson JK.Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn’s disease.PLoS One 2012;7:e49138[PMID:23209564 DOI:10.1371/journal.pone.0049138]
42 McLaughlin SD,Walker AW,Churcher C,Clark SK,Tekkis PP,Johnson MW,Parkhill J,Ciclitira PJ,Dougan G,Nicholls RJ,Petrovska L.The bacteriology of pouchitis:a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.Ann Surg 2010;252:90-98[PMID:20562611 DOI:10 .1097/SLA.0b013e3181e3dc8b]
43 Castells A,Castellví-Bel S,Balaguer F.Concepts in familial colorectal cancer:where do we stand and what is the future?Gastroenterology 2009;137:404-409[PMID:19540838 DOI:10 .1053/j.gastro.2009.06.015]
44 Zhu Q,Gao R,Wu W,Qin H.The role of gut microbiota in the pathogenesis of colorectal cancer.Tumour Biol 2013;34:1285-1300[PMID:23397545 DOI:10.1007/s13277-013-0684-4]
45 TerziJ,Grivennikov S,Karin E,Karin M.Inflammation and colon cancer.Gastroenterology 2010;138:2101-2114.e5[PMID:20420949 DOI:10.1053/j.gastro.2010.01.058]
46 Wu S,Rhee KJ,Albesiano E,Rabizadeh S,Wu X,Yen HR,Huso DL,Brancati FL,Wick E,McAllister F,Housseau F,Pardoll DM,Sears CL.A human colonic commensal promotes colon tumorigenesis via activation of T helper type17 T cell responses.Nat Med 2009;15:1016-1022[PMID:19701202 DOI:10.1038/nm.2015]
47 Azcárate-Peril MA,Sikes M,Bruno-Bárcena JM.The intestinal microbiota,gastrointestinal environment and colorectalcancer:a putative role for probiotics in prevention of colorectal cancer?Am J Physiol Gastrointest Liver Physiol 2011;301:G401-G424[PMID:21700901 DOI:10.1152/ajpgi.00110.2011]
48 Scanlan PD,Shanahan F,Clune Y,Collins JK,O’Sullivan GC,O’Riordan M,Holmes E,Wang Y,Marchesi JR.Cultureindependent analysis of the gut microbiota in colorectal cancer and polyposis.Environ Microbiol 2008;10:789-798[PMID:18237311 DOI:10.1111/j.1462-2920.2007.01503.x]
49 Uronis JM,Mühlbauer M,Herfarth HH,Rubinas TC,Jones GS,Jobin C.Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.PLoS One 2009;4:e6026[PMID:19551144 DOI:10.1371/journal.pone.0006026]
50 Shaheen NJ,Hansen RA,Morgan DR,Gangarosa LM,Ringel Y,Thiny MT,Russo MW,Sandler RS.The burden of gastrointestinal and liver diseases,2006.Am J Gastroenterol 2006;101 :2128-2138[PMID:16848807]
51 Simrén M,Barbara G,Flint HJ,Spiegel BM,Spiller RC,Vanner S,Verdu EF,Whorwell PJ,Zoetendal EG.Intestinal microbiota in functional bowel disorders:a Rome foundation report.Gut 2013;62:159-176[PMID:22730468 DOI:10.1136/gutjnl-2012-302167]
52 Spiller R,Garsed K.Infection,inflammation,and the irritable bowel syndrome.Dig Liver Dis 2009;41:844-849[PMID:19716778 DOI:10.1016/j.dld.2009.07.007]
53 Dunlop SP,Jenkins D,Neal KR,Spiller RC.Relative importance of enterochromaffin cell hyperplasia,anxiety,and depression in postinfectious IBS.Gastroenterology 2003;125:1651-1659[PMID:14724817]
54 Swan C,Duroudier NP,Campbell E,Zaitoun A,Hastings M,Dukes GE,Cox J,Kelly FM,Wilde J,Lennon MG,Neal KR,Whorwell PJ,Hall IP,Spiller RC.Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome(IBS):association with TNFSF15 and TNFα.Gut 2013;62:985-994[PMID:22684480 DOI:10.1136/gutjnl-2011-301213]
55 Ford AC,Spiegel BM,Talley NJ,Moayyedi P.Small intestinal bacterial overgrowth in irritable bowel syndrome:systematic review and meta-analysis.Clin Gastroenterol Hepatol 2009;7:1279-1286[PMID:19602448 DOI:10.1016/j.cgh.2009.06.031]
56 Spiegel BM.Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome:an epidemiologic and evolutionary perspective.Clin Gastroenterol Hepatol 2011;9:461-469;quiz e59[PMID:21397724 DOI:10.1016/j.cgh.2011.02.030]
57 Tack J.Antibiotic therapy for the irritable bowel syndrome.N Engl J Med 2011;364:81-82[PMID:21208112 DOI:10.1056/NEJMe1011211]
58 Halmos EP,Power VA,Shepherd SJ,Gibson PR,Muir JG.A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.Gastroenterology 2014;146:67-75.e5[PMID:24076059 DOI:10.1053/j.gastro.2013.09.046]
59 Ringel Y,Maharshak N.Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol 2013;305:G529-G541[PMID:23886861 DOI:10.1152/ajpgi.00207.2012]
60 Carroll IM,Ringel-Kulka T,Siddle JP,Ringel Y.Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.Neurogastroenterol Motil 2012;24:521-530,e248[PMID:22339879 DOI:10.1111/j.1365-2982.2012.01891.x]
61 Maukonen J,Satokari R,MttJ,Sderlund H,MattilaSandholm T,Saarela M.Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria.J Med Microbiol 2006;55 :625-633[PMID:16585652]
62 Parkes GC,Rayment NB,Hudspith BN,Petrovska L,Lomer MC,Brostoff J,Whelan K,Sanderson JD.Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome.Neurogastroenterol Motil 2012;24:31-39[PMID:22070725 DOI:10.1111/j.1365-2982.2011.01803.x]
63 Tana C,Umesaki Y,Imaoka A,Handa T,Kanazawa M,Fukudo S.Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.Neurogastroenterol Motil 2010;22:512-519,e114-115[PMID:19903265 DOI:10.1111/j.1365-2982.2009.01427.x]
64 Martínez C,Lobo B,Pigrau M,Ramos L,González-Castro AM,Alonso C,Guilarte M,GuiláM,de Torres I,Azpiroz F,Santos J,Vicario M.Diarrhoea-predominant irritable bowel syndrome:an organic disorder with structural abnormalities in the jejunal epithelial barrier.Gut 2013;62:1160-1168[PMID:22637702 DOI:10.1136/gutjnl-2012-302093]
65 Duboc H,Rainteau D,Rajca S,Humbert L,Farabos D,Maubert M,Grondin V,Jouet P,Bouhassira D,Seksik P,Sokol H,Coffin B,SabatéJM.Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.Neurogastroenterol Motil 2012;24:513-520,e246-247[PMID:22356587 DOI:10.1111/j.1365-2982.2012.01893.x]
66 Collins SM,Bercik P.The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease.Gastroenterology2009;136:2003-2014[PMID:19457424 DOI:10.1053/j.gastro.2009.01.075]
67 Bercik P.The microbiota-gut-brain axis:learning from intestinal bacteria?Gut 2011;60:288-289[PMID:21296788 DOI:10 .1136/gut.2010.226779]
68 Mayer EA,Savidge T,Shulman RJ.Brain-gut microbiome interactions and functional bowel disorders.Gastroenterology 2014;146:1500-1512[PMID:24583088 DOI:10.1053/j.gastro.2014.02.037]
69 Ceapa C,Wopereis H,Rezaki L,Kleerebezem M,Knol J,Oozeer R.Influence of fermented milk products,prebiotics and probiotics on microbiota composition and health.Best Pract Res Clin Gastroenterol 2013;27:139-155[PMID:23768559DOI:10.1016/j.bpg.2013.04.004]
70 Yeoh N,Burton JP,Suppiah P,Reid G,Stebbings S.The role of the microbiome in rheumatic diseases.Curr Rheumatol Rep 2013;15:314[PMID:23378145 DOI:10.1007/s11926-012-0314-y]
71 Ebel B,Lemetais G,Beney L,Cachon R,Sokol H,Langella P,Gervais P.Impact of probiotics on risk factors for cardiovascular diseases.A review.Crit Rev Food Sci Nutr 2014;54:175-189[PMID:24188267 DOI:10.1080/10408398.2011.579361]
72 Shanahan F.The gut microbiota in 2011:Translating the microbiota to medicine.Nat Rev Gastroenterol Hepatol 2012;9:72 -74[PMID:22183186 DOI:10.1038/nrgastro.2011.250]
73 Gupta A,Dhiman RK,Kumari S,Rana S,Agarwal R,Duseja A,Chawla Y.Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.J Hepatol 2010;53:849 -855[PMID:20675008 DOI:10.1016/j.jhep.2010.05.017]
74 Szabo G,Bala S,Petrasek J,Gattu A.Gut-liver axis and sensing microbes.Dig Dis 2010;28:737-744[PMID:21525758DOI:10.1159/000324281]
75 Victor DW,Quigley EM.Hepatic encephalopathy involves interactions among the microbiota,gut,brain.Clin Gastroenterol Hepatol 2014;12:1009-1011[PMID:24462627 DOI:10 .1016/j.cgh.2014.01.022]
76 Turnbaugh PJ,Ley RE,Mahowald MA,Magrini V,Mardis ER,Gordon JI.An obesity-associated gut microbiome with increased capacity for energy harvest.Nature 2006;444:1027-1031[PMID:17183312]
77 Vajro P,Paolella G,Fasano A.Microbiota and gut-liver axis:their influences on obesity and obesity-related liver disease.J Pediatr Gastroenterol Nutr 2013;56:461-468[PMID:23287807DOI:10.1097/MPG.0b013e318284abb5]
78 Quigley EM,Stanton C,Murphy EF.The gut microbiota and the liver.Pathophysiological and clinical implications.J Hepatol 2013;58:1020-1027[PMID:23183530 DOI:10.1016/j.jhep.2012.11.023]
79 Noverr MC,Huffnagle GB.The‘microflora hypothesis’of allergic diseases.Clin Exp Allergy 2005;35:1511-1520[PMID:16393316]
80 Riedler J,Braun-Fahrlnder C,Eder W,Schreuer M,Waser M,Maisch S,Carr D,Schierl R,Nowak D,von Mutius E.Exposure to farming in early life and development of asthma and allergy:a cross-sectional survey.Lancet 2001;358:1129-1133[PMID:11597666]
81 Ege MJ,Mayer M,Normand AC,Genuneit J,Cookson WO,Braun-Fahrlnder C,Heederik D,Piarroux R,von Mutius E.Exposure to environmental microorganisms and childhood asthma.N Engl J Med 2011;364:701-709[PMID:21345099DOI:10.1056/NEJMoa1007302]
82 Omland,Hjort C,Pedersen OF,Miller MR,Sigsgaard T.New-onset asthma and the effect of environment and occupation among farming and nonfarming rural subjects.J Allergy Clin Immunol 2011;128:761-765[PMID:21752438 DOI:10 .1016/j.jaci.2011.06.006]
83 Ouwehand AC,Isolauri E,He F,Hashimoto H,Benno Y,Salminen S.Differences in Bifidobacterium flora composition in allergic and healthy infants.J Allergy Clin Immunol 2001;108 :144-145[PMID:11447399]
84 Gollwitzer ES,Marsland BJ.Microbiota abnormalities in inflammatory airway diseases-Potential for therapy.Pharmacol Ther 2014;141:32-39[PMID:23969226 DOI:10.1016/j.pharmthera.2013.08.002]
85 Lynch SV,Goldfarb KC,Wild YK,Kong W,De Lisle RC,Brodie EL.Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.Gut Microbes 2013;4:41-47[PMID:23060053 DOI:10 .4161/gmic.22430]
86 Schippa S,Iebba V,Santangelo F,Gagliardi A,De Biase RV,Stamato A,Bertasi S,Lucarelli M,Conte MP,Quattrucci S.Cystic fibrosis transmembrane conductance regulator(CFTR)allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.PLoS One 2013;8:e61176[PMID:23613805DOI:10.1371/journal.pone.0061176]
87 Duytschaever G,Huys G,Bekaert M,Boulanger L,De Boeck K,Vandamme P.Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings.Appl Environ Microbiol 2011;77:8015-8024[PMID:21926193 DOI:10.1128/AEM.05933-11]
88 Madan JC,Koestler DC,Stanton BA,Davidson L,Moulton LA,Housman ML,Moore JH,Guill MF,Morrison HG,Sogin ML,Hampton TH,Karagas MR,Palumbo PE,Foster JA,Hibberd PL,O’Toole GA.Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy:interaction between intestinal and respiratory tracts and impact of nutritional exposures.MBio 2012;3:pii:e00251-12[PMID:22911969 DOI:10.1128/mBio.00251-12]
89 Forsythe P.Probiotics and lung diseases.Chest 2011;139:901 -908[PMID:21467057 DOI:10.1378/chest.10-1861]
90 Margolles A,Ruas-Madiedo P,de los Reyes-Gavilán CG,Sánchez B,Gueimonde M.Bifidobacterium.In:Liu D,editor.Molecular Detection of human bacterial pathogens.Florida:CRC Press,Taylor&Francis Group,2011:45-57
91 Turroni F,Marchesi JR,Foroni E,Gueimonde M,Shanahan F,Margolles A,van Sinderen D,Ventura M.Microbiomic analysis of the bifidobacterial population in the human distal gut.ISME J 2009;3:745-751[PMID:19295640 DOI:10.1038/ismej.2009.19]
92 Masco L,Huys G,De Brandt E,Temmerman R,Swings J.Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria.Int J Food Microbiol 2005;102:221-230[PMID:15992621]
93 Gueimonde M,Ouwehand A,PitklK,Strandberg T,Finne-Soveri H,Salminen S.Fecal Bifidobacterium levels in elderly nursing home patients-Are levels as expected?Biosci Microflora 2010;29:111-113
94 He F,Ouwehand AC,Isolauri E,Hashimoto H,Benno Y,Salminen S.Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants.FEMS Immunol Med Microbiol 2001;30:43-47[PMID:11172990]
95 Kalliomki M,Kirjavainen P,Eerola E,Kero P,Salminen S,Isolauri E.Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing.J Allergy Clin Immunol 2001;107:129-134[PMID:11150002]
96 Malinen E,RinttilT,Kajander K,MttJ,Kassinen A,Krogius L,Saarela M,Korpela R,Palva A.Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.Am J Gastroenterol 2005;100:373 -382[PMID:15667495]
97 Kerckhoffs AP,Samsom M,van der Rest ME,de Vogel J,Knol J,Ben-Amor K,Akkermans LM.Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients.World J Gastroenterol 2009;15:2887-2892[PMID:19533811]
98 Favier C,Neut C,Mizon C,Cortot A,Colombel JF,Mizon J.Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn’s disease.Dig Dis Sci 1997;42:817-822[PMID:9125655]
99 Seksik P,Rigottier-Gois L,Gramet G,Sutren M,Pochart P,Marteau P,Jian R,DoréJ.Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon.Gut 2003;52:237-242[PMID:12524406]
100 Macfarlane S,Furrie E,Cummings JH,Macfarlane GT.Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.Clin Infect Dis 2004;38:1690-1699[PMID:15227614]
101 Mylonaki M,Rayment NB,Rampton DS,Hudspith BN,Brostoff J.Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.Inflamm Bowel Dis 2005;11:481-487[PMID:15867588]
102 Gueimonde M,Ouwehand A,Huhtinen H,Salminen E,Salminen S.Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer,diverticulitis and inflammatory bowel disease.World J Gastroenterol 2007;13:3985-3989[PMID:17663515]
103 Sanz Y,Sánchez E,Marzotto M,Calabuig M,Torriani S,Dellaglio F.Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis.FEMS Immunol Med Microbiol2007;51:562-568[PMID:17919298]
104 Collado MC,Donat E,Ribes-Koninckx C,Calabuig M,Sanz Y.Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease.BMC Microbiol 2008;8:232[PMID:19102766 DOI:10 .1186/1471-2180-8-232]
105 Collado MC,Isolauri E,Laitinen K,Salminen S.Effect of mother’s weight on infant’s microbiota acquisition,composition,and activity during early infancy:a prospective follow-up study initiated in early pregnancy.Am J Clin Nutr 2010;92:1023-1030[PMID:20844065 DOI:10.3945/ajcn.2010.29877]
106 World Health Organization-Food and Agriculture Organization.Probiotics in foods.Health and nutritional properties and guidelines for evaluation,FAO Food and Nutritional Paper.Rome:FAO/WHO,2006:No.8592-5-105513-0
107 Tissier H.Traitement des infections intestinales par la mé-thod de la flore bactérienne de línstein.Crit Rev Soc Biol 1906;60:359-361
108 Vasiljevic T,Shah NP.Probiotics-from Metchnikoff to bioactives.Int Dairy J 2008;18:714-728[DOI:10.1016/j.idairyj.2008.03.004]
109 Allen SJ,Martinez EG,Gregorio GV,Dans LF.Probiotics for treating acute infectious diarrhoea.Cochrane Data-base Syst Rev 2010;(11):CD003048[PMID:21069673 DOI:10 .1002/14651858.CD003048.pub3]
110 Johnston BC,Goldenberg JZ,Vandvik PO,Sun X,Guyatt GH.Probiotics for the prevention of pediatric antibioticassociated diarrhea.Cochrane Database Syst Rev 2011;(11):CD004827[PMID:22071814 DOI:10.1002/14651858.CD004827.pub3]
111 Bernaola Aponte G,Bada Mancilla CA,Carreazo NY,Rojas Galarza RA.Probiotics for treating persistent diarrhoea in children.Cochrane Database Syst Rev 2013;8:CD007401[PMID:23963712 DOI:10.1002/14651858.CD007401.pub3]
112 Pillai A,Nelson R.Probiotics for treatment of Clostridium difficile-associated colitis in adults.Cochrane Database Syst Rev 2008;(1):CD004611[PMID:18254055 DOI:10 .1002/14651858.CD004611.pub2]
113 Goldenberg JZ,Ma SS,Saxton JD,Martzen MR,Vandvik PO,Thorlund K,Guyatt GH,Johnston BC.Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.Cochrane Database Syst Rev 2013;5 :CD006095[PMID:23728658 DOI:10.1002/14651858.CD006095.pub3]
114 Alfaleh K,Anabrees J,Bassler D,Al-Kharfi T.Probiotics for prevention of necrotizing enterocolitis in preterm infants.Cochrane Database Syst Rev 2011;(3):CD005496[PMID:21412889 DOI:10.1002/14651858.CD005496.pub3]
115 Mallon P,McKay D,Kirk S,Gardiner K.Probiotics for induction of remission in ulcerative colitis.Cochrane Database Syst Rev 2007;(4):CD005573[PMID:17943867]
116 Holubar SD,Cima RR,Sandborn WJ,Pardi DS.Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.Cochrane Database Syst Rev2010;(6):CD001176[PMID:20556748 DOI:10.1002/14651858.CD001176.pub2]
117 Naidoo K,Gordon M,Fagbemi AO,Thomas AG,Akobeng AK.Probiotics for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev 2011;(12):CD007443[PMID:22161412 DOI:10.1002/14651858.CD007443.pub2]
118 Rolfe VE,Fortun PJ,Hawkey CJ,Bath-Hextall F.Probiotics for maintenance of remission in Crohn’s disease.Cochrane Database Syst Rev 2006;(4):CD004826[PMID:17054217]
119 Butterworth AD,Thomas AG,Akobeng AK.Probiotics for induction of remission in Crohn’s disease.Cochrane Database Syst Rev 2008;(3):CD006634[PMID:18646162 DOI:10 .1002/14651858.CD006634.pub2]
120 Doherty G,Bennett G,Patil S,Cheifetz A,Moss AC.Interventions for prevention of post-operative recurrence of Crohn’s disease.Cochrane Database Syst Rev 2009;(4):CD006873[PMID:19821389 DOI:10.1002/14651858.CD006873.pub2]
121 Lirussi F,Mastropasqua E,Orando S,Orlando R.Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.Cochrane Database Syst Rev 2007;(1):CD005165[PMID:17253543]
122 McGee RG,Bakens A,Wiley K,Riordan SM,Webster AC.Probiotics for patients with hepatic encephalopathy.Cochrane Database Syst Rev 2011;(11):CD008716[PMID:22071855DOI:10.1002/14651858.CD008716.pub2]
123 Senok AC,Verstraelen H,Temmerman M,Botta GA.Probiotics for the treatment of bacterial vaginosis.Cochrane Database Syst Rev 2009;(4):CD006289[PMID:19821358 DOI:10 .1002/14651858.CD006289.pub2]
124 Othman M,Neilson JP,Alfirevic Z.Probiotics for preventing preterm labour.Cochrane Database Syst Rev 2007;(1):CD005941[PMID:17253567]
125 Osborn DA,Sinn JK.Probiotics in infants for prevention of allergic disease and food hypersensitivity.Cochrane Database Syst Rev 2007;(4):CD006475[PMID:17943912]
126 Boyle RJ,Bath-Hextall FJ,Leonardi-Bee J,Murrell DF,Tang ML.Probiotics for treating eczema.Cochrane Database Syst Rev 2008;(4):CD006135[PMID:18843705 DOI:10 .1002/14651858.CD006135.pub2]
127 Hao Q,Lu Z,Dong BR,Huang CQ,Wu T.Probiotics for preventing acute upper respiratory tract infections.Cochrane Database Syst Rev 2011;(9):CD006895[PMID:21901706 DOI:10 .1002/14651858.CD006895.pub2]
128 World Gastroenterology Organisation.World Gastroenterology Organisation Global Guidelines:Probiotics and Prebiotics,2011.Available from:URL:http://www.worldgastroenterology.org/probiotics-prebiotics.html
129 Corrêa NB,Péret Filho LA,Penna FJ,Lima FM,Nicoli JR.A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibioticassociated diarrhea in infants.J Clin Gastroenterol 2005;39:385 -389[PMID:15815206]
130 Weizman Z,Asli G,Alsheikh A.Effect of a probiotic infant formula on infections in child care centers:comparison of two probiotic agents.Pediatrics 2005;115:5-9[PMID:15629974]
131 Kajander K,Myllyluoma E,Rajili-StojanoviM,Kyrnpalo S,Rasmussen M,JrvenpS,Zoetendal EG,de Vos WM,Vapaatalo H,Korpela R.Clinical trial:multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.Aliment Pharmacol Ther 2008;27:48-57[PMID:17919270]
132 Guyonnet D,Chassany O,Ducrotte P,Picard C,Mouret M,Mercier CH,Matuchansky C.Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the healthrelated quality of life and symptoms in irritable bowel syndrome in adults in primary care:a multicentre,randomized,double-blind,controlled trial.Aliment Pharmacol Ther 2007;26 :475-486[PMID:17635382]
133 Agrawal A,Houghton LA,Morris J,Reilly B,Guyonnet D,Goupil Feuillerat N,Schlumberger A,Jakob S,Whorwell PJ.Clinical trial:the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.Aliment Pharmacol Ther 2009;29:104-114[PMID:18801055 DOI:10.1111/j.1365-2036.2008.03853.x]
134 Guyonnet D,Schlumberger A,Mhamdi L,Jakob S,Chassany O.Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms:a randomised,double-blind,parallel,controlled study.Br J Nutr 2009;102:1654-1662[PMID:19622191 DOI:10 .1017/S0007114509990882]
135 Marteau P,Guyonnet D,Lafaye de Micheaux P,Gelu S.A randomized,double-blind,controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms.Neurogastroenterol Motil 2013;25:331-e252[PMID:23480238 DOI:10.1111/nmo.12078]
136 Tillisch K,Labus J,Kilpatrick L,Jiang Z,Stains J,Ebrat B,Guyonnet D,Legrain-Raspaud S,Trotin B,Naliboff B,Mayer EA.Consumption of fermented milk product with probiotic modulates brain activity.Gastroenterology 2013;144 :1394-1401,1401.e1-4[PMID:23474283 DOI:10.1053/j.gastro.2013.02.043]
137 Waller PA,Gopal PK,Leyer GJ,Ouwehand AC,Reifer C,Stewart ME,Miller LE.Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.Scand J Gastroenterol2011;46:1057-1064[PMID:21663486 DOI:10.3109/00365521.2011.584895]
138 Lin HC,Hsu CH,Chen HL,Chung MY,Hsu JF,Lien RI,Tsao LY,Chen CH,Su BH.Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants:a multicenter,randomized,controlled trial.Pediatrics 2008;122 :693-700[PMID:18829790 DOI:10.1542/peds.2007-3007]
139 Kajander K,Hatakka K,Poussa T,FrkkilM,Korpela R.A probiotic mixture alleviates symptoms in irritable bowelsyndrome patients:a controlled 6-month intervention.Aliment Pharmacol Ther 2005;22:387-394[PMID:16128676]
140 Ishikawa H,Matsumoto S,Ohashi Y,Imaoka A,Setoyama H,Umesaki Y,Tanaka R,Otani T.Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis:a randomized controlled study.Digestion2011;84:128-133[PMID:21525768 DOI:10.1159/000322977]
141 Almeida CC,Lorena SL,Pavan CR,Akasaka HM,Mesquita MA.Beneficial effects of long-term consumption of a probiotic combination of Lactobacillus casei Shirota and Bifidobacterium breve Yakult may persist after suspension of therapy in lactose-intolerant patients.Nutr Clin Pract 2012;27:247 -251[PMID:22402407 DOI:10.1177/0884533612440289]
142 O’Mahony L,McCarthy J,Kelly P,Hurley G,Luo F,Chen K,O’Sullivan GC,Kiely B,Collins JK,Shanahan F,Quigley EM.Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles.Gastroenterology 2005;128:541-551[PMID:15765388]
143 Whorwell PJ,Altringer L,Morel J,Bond Y,Charbonneau D,O’Mahony L,Kiely B,Shanahan F,Quigley EM.Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.Am J Gastroenterol2006;101:1581-1590[PMID:16863564]
144 Groeger D,O’Mahony L,Murphy EF,Bourke JF,Dinan TG,Kiely B,Shanahan F,Quigley EM.Bifidobacterium infantis35624 modulates host inflammatory processes beyond the gut.Gut Microbes 2013;4:325-339[PMID:23842110 DOI:10 .4161/gmic.25487]
145 Lin HC,Su BH,Chen AC,Lin TW,Tsai CH,Yeh TF,Oh W.Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.Pediatrics2005;115:1-4[PMID:15629973]
146 Bin-Nun A,Bromiker R,Wilschanski M,Kaplan M,Rudensky B,Caplan M,Hammerman C.Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.J Pediatr 2005;147:192-196[PMID:16126048]
147 Miele E,Pascarella F,Giannetti E,Quaglietta L,Baldassano RN,Staiano A.Effect of a probiotic preparation(VSL#3)on induction and maintenance of remission in children with ulcerative colitis.Am J Gastroenterol 2009;104:437-443[PMID:19174792 DOI:10.1038/ajg.2008.118]
148 Guandalini S,MagazzùG,Chiaro A,La Balestra V,Di Nardo G,Gopalan S,Sibal A,Romano C,Canani RB,Lionetti P,Setty M.VSL#3 improves symptoms in children with irritable bowel syndrome:a multicenter,randomized,placebo-controlled,double-blind,crossover study.J Pediatr Gastroenterol Nutr 2010;51:24-30[PMID:20453678 DOI:10 .1097/MPG.0b013e3181ca4d95]
149 Sood A,Midha V,Makharia GK,Ahuja V,Singal D,Goswami P,Tandon RK.The probiotic preparation,VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.Clin Gastroenterol Hepatol 2009;7:1202-1209,1209.e1[PMID:19631292 DOI:10.1016/j.cgh.2009.07.016]
150 Tursi A,Brandimarte G,Papa A,Giglio A,Elisei W,Giorgetti GM,Forti G,Morini S,Hassan C,Pistoia MA,Modeo ME,Rodino’S,D’Amico T,Sebkova L,Sacca’N,Di Giulio E,Luzza F,Imeneo M,Larussa T,Di Rosa S,Annese V,Danese S,Gasbarrini A.Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment:a double-blind,randomized,placebo-controlled study.Am J Gastroenterol 2010;105:2218-2227[PMID:20517305 DOI:10.1038/ajg.2010.218]
151 Gionchetti P,Rizzello F,Helwig U,Venturi A,Lammers KM,Brigidi P,Vitali B,Poggioli G,Miglioli M,Campieri M.Prophylaxis of pouchitis onset with probiotic therapy:a double-blind,placebo-controlled trial.Gastroenterology 2003;124 :1202-1209[PMID:12730861]
152 Mimura T,Rizzello F,Helwig U,Poggioli G,Schreiber S,Talbot IC,Nicholls RJ,Gionchetti P,Campieri M,Kamm MA.Once daily high dose probiotic therapy(VSL#3)for maintaining remission in recurrent or refractory pouchitis.Gut 2004;53:108-114[PMID:14684584]
153 Pronio A,Montesani C,Butteroni C,Vecchione S,Mumolo G,Vestri A,Vitolo D,Boirivant M.Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.Inflamm Bowel Dis 2008;14:662-668[PMID:18240282DOI:10.1002/ibd.20369]
154 Selinger CP,Bell A,Cairns A,Lockett M,Sebastian S,Haslam N.Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind,randomized,placebo-controlled clinical trial.J Hosp Infect 2013;84:159-165[PMID:23618760DOI:10.1016/j.jhin.2013.02.019]
155 van der Aa LB,van Aalderen WM,Heymans HS,Henk Sillevis Smitt J,Nauta AJ,Knippels LM,Ben Amor K,Sprikkelman AB.Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis.Allergy 2011;66:170-177[PMID:20560907 DOI:10.1111/j.1398-9995.2010.02416.x]
156 Perrin Y,Nutten S,Audran R,Berger B,Bibiloni R,Wassenberg J,Barbier N,Aubert V,Moulin J,Singh A,Magliola C,Mercenier A,Spertini F.Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461in patients with allergic rhinitis.Clin Transl Allergy 2014;4:1[PMID:24393277 DOI:10.1186/2045-7022-4-1]
157 Singh A,Hacini-Rachinel F,Gosoniu ML,Bourdeau T,Holvoet S,Doucet-Ladeveze R,Beaumont M,Mercenier A,Nutten S.Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen:an exploratory,randomized,placebo-controlled clinical trial.Eur J Clin Nutr 2013;67:161 -167[PMID:23299716 DOI:10.1038/ejcn.2012.197]
158 Xiao JZ,Kondo S,Yanagisawa N,Takahashi N,Odamaki T,Iwabuchi N,Iwatsuki K,Kokubo S,Togashi H,Enomoto K,Enomoto T.Effect of probiotic Bifidobacterium longum BB536[corrected]in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season.A randomized double-blind,placebo-controlled trial.J Investig Allergol Clin Immunol 2006;16 :86-93[PMID:16689181]
159 Odamaki T,Xiao JZ,Iwabuchi N,Sakamoto M,Takahashi N,Kondo S,Miyaji K,Iwatsuki K,Togashi H,Enomoto T,Benno Y.Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season.J Med Microbiol 2007;56:1301-1308[PMID:17893165]
160 Ouwehand AC,Nermes M,Collado MC,Rautonen N,Salminen S,Isolauri E.Specific probiotics alleviate allergic rhinitis during the birch pollen season.World J Gastroenterol2009;15:3261-3268[PMID:19598302]
2 Gill SR,Pop M,Deboy RT,Eckburg PB,Turnbaugh PJ,Samuel BS,Gordon JI,Relman DA,Fraser-Liggett CM,Nelson KE.Metagenomic analysis of the human distal gut microbiome.Science 2006;312:1355-1359[PMID:16741115 DOI:10 .1126/science.1124234]
3 Kim BS,Jeon YS,Chun J.Current status and future promise of the human microbiome.Pediatr Gastroenterol Hepatol Nutr 2013;16:71-79[PMID:24010110 DOI:10.5223/pghn.2013.16.2.71]
4 Eckburg PB,Bik EM,Bernstein CN,Purdom E,Dethlefsen L,Sargent M,Gill SR,Nelson KE,Relman DA.Diversity of the human intestinal microbial flora.Science 2005;308:1635-1638[PMID:15831718 DOI:10.1126/science.1110591]
5 Arumugam M,Raes J,Pelletier E,Le Paslier D,Yamada T,Mende DR,Fernandes GR,Tap J,Bruls T,Batto JM,Bertalan M,Borruel N,Casellas F,Fernandez L,Gautier L,Hansen T,Hattori M,Hayashi T,Kleerebezem M,Kurokawa K,Leclerc M,Levenez F,Manichanh C,Nielsen HB,Nielsen T,Pons N,Poulain J,Qin J,Sicheritz-Ponten T,Tims S,Torrents D,Ugarte E,Zoetendal EG,Wang J,Guarner F,Pedersen O,de Vos WM,Brunak S,DoréJ,Antolín M,Artiguenave F,Blottiere HM,Almeida M,Brechot C,Cara C,Chervaux C,Cultrone A,Delorme C,Denariaz G,Dervyn R,Foerstner KU,Friss C,van de Guchte M,Guedon E,Haimet F,HuberW,van Hylckama-Vlieg J,Jamet A,Juste C,Kaci G,Knol J,Lakhdari O,Layec S,Le Roux K,Maguin E,Mérieux A,Melo Minardi R,M’rini C,Muller J,Oozeer R,Parkhill J,Renault P,Rescigno M,Sanchez N,Sunagawa S,Torrejon A,Turner K,Vandemeulebrouck G,Varela E,Winogradsky Y,Zeller G,Weissenbach J,Ehrlich SD,Bork P.Enterotypes of the human gut microbiome.Nature 2011;473:174-180[PMID:21508958DOI:10.1038/nature09944]
6 Lozupone CA,Stombaugh JI,Gordon JI,Jansson JK,Knight R.Diversity,stability and resilience of the human gut microbiota.Nature 2012;489:220-230[PMID:22972295 DOI:10 .1038/nature11550]
7 Arboleya S,Solís G,Fernández N,de los Reyes-Gavilán CG,Gueimonde M.Facultative to strict anaerobes ratio in the preterm infant microbiota:a target for intervention?Gut Microbes 2012;3:583-588[PMID:22922559 DOI:10.4161/gmic.21942]
8 Claesson MJ,Cusack S,O’Sullivan O,Greene-Diniz R,de Weerd H,Flannery E,Marchesi JR,Falush D,Dinan T,Fitzgerald G,Stanton C,van Sinderen D,O’Connor M,Harnedy N,O’Connor K,Henry C,O’Mahony D,Fitzgerald AP,Shanahan F,Twomey C,Hill C,Ross RP,O’Toole PW.Composition,variability,and temporal stability of the intestinal microbiota of the elderly.Proc Natl Acad Sci USA2011;108 Suppl 1:4586-4591[PMID:20571116 DOI:10.1073/pnas.1000097107]
9 Salazar N,López P,Valdés L,Margolles A,Suárez A,Patterson AM,Cuervo A,de los Reyes-Gavilán CG,Ruas-Madiedo P,González S,Gueimonde M.Microbial targets for the development of functional foods accordingly with nutritional and immune parameters altered in the elderly.J Am Coll Nutr 2013;32:399-406[DOI:10.1080/07315724.2013.827047]
10 Cani PD,Everard A,Duparc T.Gut microbiota,enteroendocrine functions and metabolism.Curr Opin Pharmacol 2013;13:935-940[PMID:24075718 DOI:10.1016/j.coph.2013.09.008]
11 Reigstad CS,Kashyap PC.Beyond phylotyping:understanding the impact of gut microbiota on host biology.Neurogastroenterol Motil 2013;25:358-372[PMID:23594242 DOI:10 .1111/nmo.12134]
12 Flint HJ,Scott KP,Louis P,Duncan SH.The role of the gut microbiota in nutrition and health.Nat Rev Gastroenterol Hepatol 2012;9:577-589[PMID:22945443 DOI:10.1038/nrgastro.2012.156]
13 Sjgren YM,Tomicic S,Lundberg A,Bttcher MF,Bjrkstén B,Sverremark-Ekstrm E,Jenmalm MC.Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses.Clin Exp Allergy 2009;39:1842-1851[PMID:19735274 DOI:10.1111/j.1365-2222.2009.03326.x]
14 Martin R,Nauta AJ,Ben Amor K,Knippels LM,Knol J,Garssen J.Early life:gut microbiota and immune development in infancy.Benef Microbes 2010;1:367-382[PMID:21831776 DOI:10.3920/BM2010.0027]
15 Hsiao EY,McBride SW,Hsien S,Sharon G,Hyde ER,McCue T,Codelli JA,Chow J,Reisman SE,Petrosino JF,Patterson PH,Mazmanian SK.Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders.Cell 2013;155:1451-1463[PMID:24315484DOI:10.1016/j.cell.2013.11.024]
16 Wu GD,Chen J,Hoffmann C,Bittinger K,Chen YY,Keilbaugh SA,Bewtra M,Knights D,Walters WA,Knight R,Sinha R,Gilroy E,Gupta K,Baldassano R,Nessel L,Li H,Bushman FD,Lewis JD.Linking long-term dietary patterns with gut microbial enterotypes.Science 2011;334:105-108[PMID:21885731 DOI:10.1126/science.1208344]
17 Yatsunenko T,Rey FE,Manary MJ,Trehan I,DominguezBello MG,Contreras M,Magris M,Hidalgo G,Baldassano RN,Anokhin AP,Heath AC,Warner B,Reeder J,Kuczynski J,Caporaso JG,Lozupone CA,Lauber C,Clemente JC,KnightsD,Knight R,Gordon JI.Human gut microbiome viewed across age and geography.Nature 2012;486:222-227[PMID:22699611 DOI:10.1038/nature11053]
18 Arboleya S,Ang L,Margolles A,Yiyuan L,Dongya Z,Liang X,Solís G,Fernández N,de Los Reyes-Gavilán CG,Gueimonde M.Deep 16S rRNA metagenomics and quantitative PCR analyses of the premature infant fecal microbiota.Anaerobe 2012;18:378-380[PMID:22579986 DOI:10.1016/j.anaerobe.2012.04.013]
19 Pérez-Cobas AE,Artacho A,Knecht H,Ferrús ML,Friedrichs A,Ott SJ,Moya A,Latorre A,Gosalbes MJ.Differential effects of antibiotic therapy on the structure and function of human gut microbiota.PLoS One 2013;8:e80201[PMID:24282523 DOI:10.1371/journal.pone.0080201]
20 Aziz Q,DoréJ,Emmanuel A,Guarner F,Quigley EM.Gut microbiota and gastrointestinal health:current concepts and future directions.Neurogastroenterol Motil 2013;25:4-15[PMID:23279728 DOI:10.1111/nmo.12046]
21 Wu GD,Lewis JD.Analysis of the human gut microbiome and association with disease.Clin Gastroenterol Hepatol 2013;11 :774-777[PMID:23643636 DOI:10.1016/j.cgh.2013.03.038]
22 Shanahan F,Quigley EM.Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies.Gastroenterology 2014;146:1554-1563[PMID:24486051 DOI:10 .1053/j.gastro.2014.01.050]
23 Fraher MH,O’Toole PW,Quigley EM.Techniques used to characterize the gut microbiota:a guide for the clinician.Nat Rev Gastroenterol Hepatol 2012;9:312-322[PMID:22450307DOI:10.1038/nrgastro.2012.44]
24 van Nood E,Vrieze A,Nieuwdorp M,Fuentes S,Zoetendal EG,de Vos WM,Visser CE,Kuijper EJ,Bartelsman JF,Tijssen JG,Speelman P,Dijkgraaf MG,Keller JJ.Duodenal infusion of donor feces for recurrent Clostridium difficile.N Engl J Med 2013;368:407-415[PMID:23323867 DOI:10.1056/NEJMoa1205037]
25 Borody TJ,Khoruts A.Fecal microbiota transplantation and emerging applications.Nat Rev Gastroenterol Hepatol 2012;9:88 -96[PMID:22183182 DOI:10.1038/nrgastro.2011.244]
26 Smits LP,Bouter KE,de Vos WM,Borody TJ,Nieuwdorp M.Therapeutic potential of fecal microbiota transplantation.Gastroenterology 2013;145:946-953[PMID:24018052 DOI:10 .1053/j.gastro.2013.08.058]
27 Sanders ME,Guarner F,Guerrant R,Holt PR,Quigley EM,Sartor RB,Sherman PM,Mayer EA.An update on the use and investigation of probiotics in health and disease.Gut 2013;62:787-796[PMID:23474420 DOI:10.1136/gutjnl-2012-302504]
28 Borody TJ,Brandt LJ,Paramsothy S.Therapeutic faecal microbiota transplantation:current status and future developments.Curr Opin Gastroenterol 2014;30:97-105[PMID:24257037 DOI:10.1097/MOG.0000000000000027]
29 Manichanh C,Borruel N,Casellas F,Guarner F.The gut microbiota in IBD.Nat Rev Gastroenterol Hepatol 2012;9:599-608[PMID:22907164 DOI:10.1038/nrgastro.2012.152]
30 Knights D,Lassen KG,Xavier RJ.Advances in inflammatory bowel disease pathogenesis:linking host genetics and the microbiome.Gut 2013;62:1505-1510[PMID:24037875 DOI:10 .1136/gutjnl-2012-303954]
31 Guarner F.What is the role of the enteric commensal flora in IBD?Inflamm Bowel Dis 2008;14 Suppl 2:S83-S84[PMID:18816773 DOI:10.1002/ibd.20548]
32 Kostic AD,Xavier RJ,Gevers D.The microbiome in inflammatory bowel disease:current status and the future ahead.Gastroenterology 2014;146:1489-1499[PMID:24560869 DOI:10 .1053/j.gastro.2014.02.009]
33 Ott SJ,Musfeldt M,Wenderoth DF,Hampe J,Brant O,Flsch UR,Timmis KN,Schreiber S.Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease.Gut 2004;53:685 -693[PMID:15082587]
34 Martinez C,Antolin M,Santos J,Torrejon A,Casellas F,Borruel N,Guarner F,Malagelada JR.Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission.Am J Gastroenterol 2008;103:643-648[PMID:18341488DOI:10.1111/j.1572-0241.2007.01592.x]
35 Chassaing B,Darfeuille-Michaud A.The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases.Gastroenterology 2011;140:1720-1728[PMID:21530738 DOI:10.1053/j.gastro.2011.01.054]
36 Rowan F,Docherty NG,Murphy M,Murphy B,Calvin Coffey J,O’Connell PR.Desulfovibrio bacterial species are increased in ulcerative colitis.Dis Colon Rectum2010;53:1530-1536[PMID:20940602 DOI:10.1007/DCR.0b013e3181f1e620]
37 Morgan XC,Tickle TL,Sokol H,Gevers D,Devaney KL,Ward DV,Reyes JA,Shah SA,LeLeiko N,Snapper SB,Bousvaros A,Korzenik J,Sands BE,Xavier RJ,Huttenhower C.Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.Genome Biol 2012;13:R79[PMID:23013615 DOI:10.1186/gb-2012-13-9-r79]
38 Sokol H,Pigneur B,Watterlot L,Lakhdari O,BermúdezHumarán LG,Gratadoux JJ,Blugeon S,Bridonneau C,Furet JP,Corthier G,Grangette C,Vasquez N,Pochart P,Trugnan G,Thomas G,Blottière HM,DoréJ,Marteau P,Seksik P,Langella P.Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.Proc Natl Acad Sci USA2008;105:16731-16736[PMID:18936492 DOI:10.1073/pnas.0804812105]
39 Willing B,Halfvarson J,Dicksved J,Rosenquist M,Jrnerot G,Engstrand L,Tysk C,Jansson JK.Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease.Inflamm Bowel Dis 2009;15 :653-660[PMID:19023901 DOI:10.1002/ibd.20783]
40 Darfeuille-Michaud A,Boudeau J,Bulois P,Neut C,Glasser AL,Barnich N,Bringer MA,Swidsinski A,Beaugerie L,Colombel JF.High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease.Gastroenterology 2004;127:412-421[PMID:15300573]
41 Erickson AR,Cantarel BL,Lamendella R,Darzi Y,Mongodin EF,Pan C,Shah M,Halfvarson J,Tysk C,Henrissat B,Raes J,Verberkmoes NC,Fraser CM,Hettich RL,Jansson JK.Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn’s disease.PLoS One 2012;7:e49138[PMID:23209564 DOI:10.1371/journal.pone.0049138]
42 McLaughlin SD,Walker AW,Churcher C,Clark SK,Tekkis PP,Johnson MW,Parkhill J,Ciclitira PJ,Dougan G,Nicholls RJ,Petrovska L.The bacteriology of pouchitis:a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.Ann Surg 2010;252:90-98[PMID:20562611 DOI:10 .1097/SLA.0b013e3181e3dc8b]
43 Castells A,Castellví-Bel S,Balaguer F.Concepts in familial colorectal cancer:where do we stand and what is the future?Gastroenterology 2009;137:404-409[PMID:19540838 DOI:10 .1053/j.gastro.2009.06.015]
44 Zhu Q,Gao R,Wu W,Qin H.The role of gut microbiota in the pathogenesis of colorectal cancer.Tumour Biol 2013;34:1285-1300[PMID:23397545 DOI:10.1007/s13277-013-0684-4]
45 TerziJ,Grivennikov S,Karin E,Karin M.Inflammation and colon cancer.Gastroenterology 2010;138:2101-2114.e5[PMID:20420949 DOI:10.1053/j.gastro.2010.01.058]
46 Wu S,Rhee KJ,Albesiano E,Rabizadeh S,Wu X,Yen HR,Huso DL,Brancati FL,Wick E,McAllister F,Housseau F,Pardoll DM,Sears CL.A human colonic commensal promotes colon tumorigenesis via activation of T helper type17 T cell responses.Nat Med 2009;15:1016-1022[PMID:19701202 DOI:10.1038/nm.2015]
47 Azcárate-Peril MA,Sikes M,Bruno-Bárcena JM.The intestinal microbiota,gastrointestinal environment and colorectalcancer:a putative role for probiotics in prevention of colorectal cancer?Am J Physiol Gastrointest Liver Physiol 2011;301:G401-G424[PMID:21700901 DOI:10.1152/ajpgi.00110.2011]
48 Scanlan PD,Shanahan F,Clune Y,Collins JK,O’Sullivan GC,O’Riordan M,Holmes E,Wang Y,Marchesi JR.Cultureindependent analysis of the gut microbiota in colorectal cancer and polyposis.Environ Microbiol 2008;10:789-798[PMID:18237311 DOI:10.1111/j.1462-2920.2007.01503.x]
49 Uronis JM,Mühlbauer M,Herfarth HH,Rubinas TC,Jones GS,Jobin C.Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.PLoS One 2009;4:e6026[PMID:19551144 DOI:10.1371/journal.pone.0006026]
50 Shaheen NJ,Hansen RA,Morgan DR,Gangarosa LM,Ringel Y,Thiny MT,Russo MW,Sandler RS.The burden of gastrointestinal and liver diseases,2006.Am J Gastroenterol 2006;101 :2128-2138[PMID:16848807]
51 Simrén M,Barbara G,Flint HJ,Spiegel BM,Spiller RC,Vanner S,Verdu EF,Whorwell PJ,Zoetendal EG.Intestinal microbiota in functional bowel disorders:a Rome foundation report.Gut 2013;62:159-176[PMID:22730468 DOI:10.1136/gutjnl-2012-302167]
52 Spiller R,Garsed K.Infection,inflammation,and the irritable bowel syndrome.Dig Liver Dis 2009;41:844-849[PMID:19716778 DOI:10.1016/j.dld.2009.07.007]
53 Dunlop SP,Jenkins D,Neal KR,Spiller RC.Relative importance of enterochromaffin cell hyperplasia,anxiety,and depression in postinfectious IBS.Gastroenterology 2003;125:1651-1659[PMID:14724817]
54 Swan C,Duroudier NP,Campbell E,Zaitoun A,Hastings M,Dukes GE,Cox J,Kelly FM,Wilde J,Lennon MG,Neal KR,Whorwell PJ,Hall IP,Spiller RC.Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome(IBS):association with TNFSF15 and TNFα.Gut 2013;62:985-994[PMID:22684480 DOI:10.1136/gutjnl-2011-301213]
55 Ford AC,Spiegel BM,Talley NJ,Moayyedi P.Small intestinal bacterial overgrowth in irritable bowel syndrome:systematic review and meta-analysis.Clin Gastroenterol Hepatol 2009;7:1279-1286[PMID:19602448 DOI:10.1016/j.cgh.2009.06.031]
56 Spiegel BM.Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome:an epidemiologic and evolutionary perspective.Clin Gastroenterol Hepatol 2011;9:461-469;quiz e59[PMID:21397724 DOI:10.1016/j.cgh.2011.02.030]
57 Tack J.Antibiotic therapy for the irritable bowel syndrome.N Engl J Med 2011;364:81-82[PMID:21208112 DOI:10.1056/NEJMe1011211]
58 Halmos EP,Power VA,Shepherd SJ,Gibson PR,Muir JG.A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.Gastroenterology 2014;146:67-75.e5[PMID:24076059 DOI:10.1053/j.gastro.2013.09.046]
59 Ringel Y,Maharshak N.Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol 2013;305:G529-G541[PMID:23886861 DOI:10.1152/ajpgi.00207.2012]
60 Carroll IM,Ringel-Kulka T,Siddle JP,Ringel Y.Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.Neurogastroenterol Motil 2012;24:521-530,e248[PMID:22339879 DOI:10.1111/j.1365-2982.2012.01891.x]
61 Maukonen J,Satokari R,MttJ,Sderlund H,MattilaSandholm T,Saarela M.Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria.J Med Microbiol 2006;55 :625-633[PMID:16585652]
62 Parkes GC,Rayment NB,Hudspith BN,Petrovska L,Lomer MC,Brostoff J,Whelan K,Sanderson JD.Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome.Neurogastroenterol Motil 2012;24:31-39[PMID:22070725 DOI:10.1111/j.1365-2982.2011.01803.x]
63 Tana C,Umesaki Y,Imaoka A,Handa T,Kanazawa M,Fukudo S.Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.Neurogastroenterol Motil 2010;22:512-519,e114-115[PMID:19903265 DOI:10.1111/j.1365-2982.2009.01427.x]
64 Martínez C,Lobo B,Pigrau M,Ramos L,González-Castro AM,Alonso C,Guilarte M,GuiláM,de Torres I,Azpiroz F,Santos J,Vicario M.Diarrhoea-predominant irritable bowel syndrome:an organic disorder with structural abnormalities in the jejunal epithelial barrier.Gut 2013;62:1160-1168[PMID:22637702 DOI:10.1136/gutjnl-2012-302093]
65 Duboc H,Rainteau D,Rajca S,Humbert L,Farabos D,Maubert M,Grondin V,Jouet P,Bouhassira D,Seksik P,Sokol H,Coffin B,SabatéJM.Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.Neurogastroenterol Motil 2012;24:513-520,e246-247[PMID:22356587 DOI:10.1111/j.1365-2982.2012.01893.x]
66 Collins SM,Bercik P.The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease.Gastroenterology2009;136:2003-2014[PMID:19457424 DOI:10.1053/j.gastro.2009.01.075]
67 Bercik P.The microbiota-gut-brain axis:learning from intestinal bacteria?Gut 2011;60:288-289[PMID:21296788 DOI:10 .1136/gut.2010.226779]
68 Mayer EA,Savidge T,Shulman RJ.Brain-gut microbiome interactions and functional bowel disorders.Gastroenterology 2014;146:1500-1512[PMID:24583088 DOI:10.1053/j.gastro.2014.02.037]
69 Ceapa C,Wopereis H,Rezaki L,Kleerebezem M,Knol J,Oozeer R.Influence of fermented milk products,prebiotics and probiotics on microbiota composition and health.Best Pract Res Clin Gastroenterol 2013;27:139-155[PMID:23768559DOI:10.1016/j.bpg.2013.04.004]
70 Yeoh N,Burton JP,Suppiah P,Reid G,Stebbings S.The role of the microbiome in rheumatic diseases.Curr Rheumatol Rep 2013;15:314[PMID:23378145 DOI:10.1007/s11926-012-0314-y]
71 Ebel B,Lemetais G,Beney L,Cachon R,Sokol H,Langella P,Gervais P.Impact of probiotics on risk factors for cardiovascular diseases.A review.Crit Rev Food Sci Nutr 2014;54:175-189[PMID:24188267 DOI:10.1080/10408398.2011.579361]
72 Shanahan F.The gut microbiota in 2011:Translating the microbiota to medicine.Nat Rev Gastroenterol Hepatol 2012;9:72 -74[PMID:22183186 DOI:10.1038/nrgastro.2011.250]
73 Gupta A,Dhiman RK,Kumari S,Rana S,Agarwal R,Duseja A,Chawla Y.Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.J Hepatol 2010;53:849 -855[PMID:20675008 DOI:10.1016/j.jhep.2010.05.017]
74 Szabo G,Bala S,Petrasek J,Gattu A.Gut-liver axis and sensing microbes.Dig Dis 2010;28:737-744[PMID:21525758DOI:10.1159/000324281]
75 Victor DW,Quigley EM.Hepatic encephalopathy involves interactions among the microbiota,gut,brain.Clin Gastroenterol Hepatol 2014;12:1009-1011[PMID:24462627 DOI:10 .1016/j.cgh.2014.01.022]
76 Turnbaugh PJ,Ley RE,Mahowald MA,Magrini V,Mardis ER,Gordon JI.An obesity-associated gut microbiome with increased capacity for energy harvest.Nature 2006;444:1027-1031[PMID:17183312]
77 Vajro P,Paolella G,Fasano A.Microbiota and gut-liver axis:their influences on obesity and obesity-related liver disease.J Pediatr Gastroenterol Nutr 2013;56:461-468[PMID:23287807DOI:10.1097/MPG.0b013e318284abb5]
78 Quigley EM,Stanton C,Murphy EF.The gut microbiota and the liver.Pathophysiological and clinical implications.J Hepatol 2013;58:1020-1027[PMID:23183530 DOI:10.1016/j.jhep.2012.11.023]
79 Noverr MC,Huffnagle GB.The‘microflora hypothesis’of allergic diseases.Clin Exp Allergy 2005;35:1511-1520[PMID:16393316]
80 Riedler J,Braun-Fahrlnder C,Eder W,Schreuer M,Waser M,Maisch S,Carr D,Schierl R,Nowak D,von Mutius E.Exposure to farming in early life and development of asthma and allergy:a cross-sectional survey.Lancet 2001;358:1129-1133[PMID:11597666]
81 Ege MJ,Mayer M,Normand AC,Genuneit J,Cookson WO,Braun-Fahrlnder C,Heederik D,Piarroux R,von Mutius E.Exposure to environmental microorganisms and childhood asthma.N Engl J Med 2011;364:701-709[PMID:21345099DOI:10.1056/NEJMoa1007302]
82 Omland,Hjort C,Pedersen OF,Miller MR,Sigsgaard T.New-onset asthma and the effect of environment and occupation among farming and nonfarming rural subjects.J Allergy Clin Immunol 2011;128:761-765[PMID:21752438 DOI:10 .1016/j.jaci.2011.06.006]
83 Ouwehand AC,Isolauri E,He F,Hashimoto H,Benno Y,Salminen S.Differences in Bifidobacterium flora composition in allergic and healthy infants.J Allergy Clin Immunol 2001;108 :144-145[PMID:11447399]
84 Gollwitzer ES,Marsland BJ.Microbiota abnormalities in inflammatory airway diseases-Potential for therapy.Pharmacol Ther 2014;141:32-39[PMID:23969226 DOI:10.1016/j.pharmthera.2013.08.002]
85 Lynch SV,Goldfarb KC,Wild YK,Kong W,De Lisle RC,Brodie EL.Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.Gut Microbes 2013;4:41-47[PMID:23060053 DOI:10 .4161/gmic.22430]
86 Schippa S,Iebba V,Santangelo F,Gagliardi A,De Biase RV,Stamato A,Bertasi S,Lucarelli M,Conte MP,Quattrucci S.Cystic fibrosis transmembrane conductance regulator(CFTR)allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.PLoS One 2013;8:e61176[PMID:23613805DOI:10.1371/journal.pone.0061176]
87 Duytschaever G,Huys G,Bekaert M,Boulanger L,De Boeck K,Vandamme P.Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings.Appl Environ Microbiol 2011;77:8015-8024[PMID:21926193 DOI:10.1128/AEM.05933-11]
88 Madan JC,Koestler DC,Stanton BA,Davidson L,Moulton LA,Housman ML,Moore JH,Guill MF,Morrison HG,Sogin ML,Hampton TH,Karagas MR,Palumbo PE,Foster JA,Hibberd PL,O’Toole GA.Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy:interaction between intestinal and respiratory tracts and impact of nutritional exposures.MBio 2012;3:pii:e00251-12[PMID:22911969 DOI:10.1128/mBio.00251-12]
89 Forsythe P.Probiotics and lung diseases.Chest 2011;139:901 -908[PMID:21467057 DOI:10.1378/chest.10-1861]
90 Margolles A,Ruas-Madiedo P,de los Reyes-Gavilán CG,Sánchez B,Gueimonde M.Bifidobacterium.In:Liu D,editor.Molecular Detection of human bacterial pathogens.Florida:CRC Press,Taylor&Francis Group,2011:45-57
91 Turroni F,Marchesi JR,Foroni E,Gueimonde M,Shanahan F,Margolles A,van Sinderen D,Ventura M.Microbiomic analysis of the bifidobacterial population in the human distal gut.ISME J 2009;3:745-751[PMID:19295640 DOI:10.1038/ismej.2009.19]
92 Masco L,Huys G,De Brandt E,Temmerman R,Swings J.Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria.Int J Food Microbiol 2005;102:221-230[PMID:15992621]
93 Gueimonde M,Ouwehand A,PitklK,Strandberg T,Finne-Soveri H,Salminen S.Fecal Bifidobacterium levels in elderly nursing home patients-Are levels as expected?Biosci Microflora 2010;29:111-113
94 He F,Ouwehand AC,Isolauri E,Hashimoto H,Benno Y,Salminen S.Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants.FEMS Immunol Med Microbiol 2001;30:43-47[PMID:11172990]
95 Kalliomki M,Kirjavainen P,Eerola E,Kero P,Salminen S,Isolauri E.Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing.J Allergy Clin Immunol 2001;107:129-134[PMID:11150002]
96 Malinen E,RinttilT,Kajander K,MttJ,Kassinen A,Krogius L,Saarela M,Korpela R,Palva A.Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.Am J Gastroenterol 2005;100:373 -382[PMID:15667495]
97 Kerckhoffs AP,Samsom M,van der Rest ME,de Vogel J,Knol J,Ben-Amor K,Akkermans LM.Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients.World J Gastroenterol 2009;15:2887-2892[PMID:19533811]
98 Favier C,Neut C,Mizon C,Cortot A,Colombel JF,Mizon J.Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn’s disease.Dig Dis Sci 1997;42:817-822[PMID:9125655]
99 Seksik P,Rigottier-Gois L,Gramet G,Sutren M,Pochart P,Marteau P,Jian R,DoréJ.Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon.Gut 2003;52:237-242[PMID:12524406]
100 Macfarlane S,Furrie E,Cummings JH,Macfarlane GT.Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.Clin Infect Dis 2004;38:1690-1699[PMID:15227614]
101 Mylonaki M,Rayment NB,Rampton DS,Hudspith BN,Brostoff J.Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.Inflamm Bowel Dis 2005;11:481-487[PMID:15867588]
102 Gueimonde M,Ouwehand A,Huhtinen H,Salminen E,Salminen S.Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer,diverticulitis and inflammatory bowel disease.World J Gastroenterol 2007;13:3985-3989[PMID:17663515]
103 Sanz Y,Sánchez E,Marzotto M,Calabuig M,Torriani S,Dellaglio F.Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis.FEMS Immunol Med Microbiol2007;51:562-568[PMID:17919298]
104 Collado MC,Donat E,Ribes-Koninckx C,Calabuig M,Sanz Y.Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease.BMC Microbiol 2008;8:232[PMID:19102766 DOI:10 .1186/1471-2180-8-232]
105 Collado MC,Isolauri E,Laitinen K,Salminen S.Effect of mother’s weight on infant’s microbiota acquisition,composition,and activity during early infancy:a prospective follow-up study initiated in early pregnancy.Am J Clin Nutr 2010;92:1023-1030[PMID:20844065 DOI:10.3945/ajcn.2010.29877]
106 World Health Organization-Food and Agriculture Organization.Probiotics in foods.Health and nutritional properties and guidelines for evaluation,FAO Food and Nutritional Paper.Rome:FAO/WHO,2006:No.8592-5-105513-0
107 Tissier H.Traitement des infections intestinales par la mé-thod de la flore bactérienne de línstein.Crit Rev Soc Biol 1906;60:359-361
108 Vasiljevic T,Shah NP.Probiotics-from Metchnikoff to bioactives.Int Dairy J 2008;18:714-728[DOI:10.1016/j.idairyj.2008.03.004]
109 Allen SJ,Martinez EG,Gregorio GV,Dans LF.Probiotics for treating acute infectious diarrhoea.Cochrane Data-base Syst Rev 2010;(11):CD003048[PMID:21069673 DOI:10 .1002/14651858.CD003048.pub3]
110 Johnston BC,Goldenberg JZ,Vandvik PO,Sun X,Guyatt GH.Probiotics for the prevention of pediatric antibioticassociated diarrhea.Cochrane Database Syst Rev 2011;(11):CD004827[PMID:22071814 DOI:10.1002/14651858.CD004827.pub3]
111 Bernaola Aponte G,Bada Mancilla CA,Carreazo NY,Rojas Galarza RA.Probiotics for treating persistent diarrhoea in children.Cochrane Database Syst Rev 2013;8:CD007401[PMID:23963712 DOI:10.1002/14651858.CD007401.pub3]
112 Pillai A,Nelson R.Probiotics for treatment of Clostridium difficile-associated colitis in adults.Cochrane Database Syst Rev 2008;(1):CD004611[PMID:18254055 DOI:10 .1002/14651858.CD004611.pub2]
113 Goldenberg JZ,Ma SS,Saxton JD,Martzen MR,Vandvik PO,Thorlund K,Guyatt GH,Johnston BC.Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.Cochrane Database Syst Rev 2013;5 :CD006095[PMID:23728658 DOI:10.1002/14651858.CD006095.pub3]
114 Alfaleh K,Anabrees J,Bassler D,Al-Kharfi T.Probiotics for prevention of necrotizing enterocolitis in preterm infants.Cochrane Database Syst Rev 2011;(3):CD005496[PMID:21412889 DOI:10.1002/14651858.CD005496.pub3]
115 Mallon P,McKay D,Kirk S,Gardiner K.Probiotics for induction of remission in ulcerative colitis.Cochrane Database Syst Rev 2007;(4):CD005573[PMID:17943867]
116 Holubar SD,Cima RR,Sandborn WJ,Pardi DS.Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.Cochrane Database Syst Rev2010;(6):CD001176[PMID:20556748 DOI:10.1002/14651858.CD001176.pub2]
117 Naidoo K,Gordon M,Fagbemi AO,Thomas AG,Akobeng AK.Probiotics for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev 2011;(12):CD007443[PMID:22161412 DOI:10.1002/14651858.CD007443.pub2]
118 Rolfe VE,Fortun PJ,Hawkey CJ,Bath-Hextall F.Probiotics for maintenance of remission in Crohn’s disease.Cochrane Database Syst Rev 2006;(4):CD004826[PMID:17054217]
119 Butterworth AD,Thomas AG,Akobeng AK.Probiotics for induction of remission in Crohn’s disease.Cochrane Database Syst Rev 2008;(3):CD006634[PMID:18646162 DOI:10 .1002/14651858.CD006634.pub2]
120 Doherty G,Bennett G,Patil S,Cheifetz A,Moss AC.Interventions for prevention of post-operative recurrence of Crohn’s disease.Cochrane Database Syst Rev 2009;(4):CD006873[PMID:19821389 DOI:10.1002/14651858.CD006873.pub2]
121 Lirussi F,Mastropasqua E,Orando S,Orlando R.Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.Cochrane Database Syst Rev 2007;(1):CD005165[PMID:17253543]
122 McGee RG,Bakens A,Wiley K,Riordan SM,Webster AC.Probiotics for patients with hepatic encephalopathy.Cochrane Database Syst Rev 2011;(11):CD008716[PMID:22071855DOI:10.1002/14651858.CD008716.pub2]
123 Senok AC,Verstraelen H,Temmerman M,Botta GA.Probiotics for the treatment of bacterial vaginosis.Cochrane Database Syst Rev 2009;(4):CD006289[PMID:19821358 DOI:10 .1002/14651858.CD006289.pub2]
124 Othman M,Neilson JP,Alfirevic Z.Probiotics for preventing preterm labour.Cochrane Database Syst Rev 2007;(1):CD005941[PMID:17253567]
125 Osborn DA,Sinn JK.Probiotics in infants for prevention of allergic disease and food hypersensitivity.Cochrane Database Syst Rev 2007;(4):CD006475[PMID:17943912]
126 Boyle RJ,Bath-Hextall FJ,Leonardi-Bee J,Murrell DF,Tang ML.Probiotics for treating eczema.Cochrane Database Syst Rev 2008;(4):CD006135[PMID:18843705 DOI:10 .1002/14651858.CD006135.pub2]
127 Hao Q,Lu Z,Dong BR,Huang CQ,Wu T.Probiotics for preventing acute upper respiratory tract infections.Cochrane Database Syst Rev 2011;(9):CD006895[PMID:21901706 DOI:10 .1002/14651858.CD006895.pub2]
128 World Gastroenterology Organisation.World Gastroenterology Organisation Global Guidelines:Probiotics and Prebiotics,2011.Available from:URL:http://www.worldgastroenterology.org/probiotics-prebiotics.html
129 Corrêa NB,Péret Filho LA,Penna FJ,Lima FM,Nicoli JR.A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibioticassociated diarrhea in infants.J Clin Gastroenterol 2005;39:385 -389[PMID:15815206]
130 Weizman Z,Asli G,Alsheikh A.Effect of a probiotic infant formula on infections in child care centers:comparison of two probiotic agents.Pediatrics 2005;115:5-9[PMID:15629974]
131 Kajander K,Myllyluoma E,Rajili-StojanoviM,Kyrnpalo S,Rasmussen M,JrvenpS,Zoetendal EG,de Vos WM,Vapaatalo H,Korpela R.Clinical trial:multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.Aliment Pharmacol Ther 2008;27:48-57[PMID:17919270]
132 Guyonnet D,Chassany O,Ducrotte P,Picard C,Mouret M,Mercier CH,Matuchansky C.Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the healthrelated quality of life and symptoms in irritable bowel syndrome in adults in primary care:a multicentre,randomized,double-blind,controlled trial.Aliment Pharmacol Ther 2007;26 :475-486[PMID:17635382]
133 Agrawal A,Houghton LA,Morris J,Reilly B,Guyonnet D,Goupil Feuillerat N,Schlumberger A,Jakob S,Whorwell PJ.Clinical trial:the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.Aliment Pharmacol Ther 2009;29:104-114[PMID:18801055 DOI:10.1111/j.1365-2036.2008.03853.x]
134 Guyonnet D,Schlumberger A,Mhamdi L,Jakob S,Chassany O.Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms:a randomised,double-blind,parallel,controlled study.Br J Nutr 2009;102:1654-1662[PMID:19622191 DOI:10 .1017/S0007114509990882]
135 Marteau P,Guyonnet D,Lafaye de Micheaux P,Gelu S.A randomized,double-blind,controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms.Neurogastroenterol Motil 2013;25:331-e252[PMID:23480238 DOI:10.1111/nmo.12078]
136 Tillisch K,Labus J,Kilpatrick L,Jiang Z,Stains J,Ebrat B,Guyonnet D,Legrain-Raspaud S,Trotin B,Naliboff B,Mayer EA.Consumption of fermented milk product with probiotic modulates brain activity.Gastroenterology 2013;144 :1394-1401,1401.e1-4[PMID:23474283 DOI:10.1053/j.gastro.2013.02.043]
137 Waller PA,Gopal PK,Leyer GJ,Ouwehand AC,Reifer C,Stewart ME,Miller LE.Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.Scand J Gastroenterol2011;46:1057-1064[PMID:21663486 DOI:10.3109/00365521.2011.584895]
138 Lin HC,Hsu CH,Chen HL,Chung MY,Hsu JF,Lien RI,Tsao LY,Chen CH,Su BH.Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants:a multicenter,randomized,controlled trial.Pediatrics 2008;122 :693-700[PMID:18829790 DOI:10.1542/peds.2007-3007]
139 Kajander K,Hatakka K,Poussa T,FrkkilM,Korpela R.A probiotic mixture alleviates symptoms in irritable bowelsyndrome patients:a controlled 6-month intervention.Aliment Pharmacol Ther 2005;22:387-394[PMID:16128676]
140 Ishikawa H,Matsumoto S,Ohashi Y,Imaoka A,Setoyama H,Umesaki Y,Tanaka R,Otani T.Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis:a randomized controlled study.Digestion2011;84:128-133[PMID:21525768 DOI:10.1159/000322977]
141 Almeida CC,Lorena SL,Pavan CR,Akasaka HM,Mesquita MA.Beneficial effects of long-term consumption of a probiotic combination of Lactobacillus casei Shirota and Bifidobacterium breve Yakult may persist after suspension of therapy in lactose-intolerant patients.Nutr Clin Pract 2012;27:247 -251[PMID:22402407 DOI:10.1177/0884533612440289]
142 O’Mahony L,McCarthy J,Kelly P,Hurley G,Luo F,Chen K,O’Sullivan GC,Kiely B,Collins JK,Shanahan F,Quigley EM.Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles.Gastroenterology 2005;128:541-551[PMID:15765388]
143 Whorwell PJ,Altringer L,Morel J,Bond Y,Charbonneau D,O’Mahony L,Kiely B,Shanahan F,Quigley EM.Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.Am J Gastroenterol2006;101:1581-1590[PMID:16863564]
144 Groeger D,O’Mahony L,Murphy EF,Bourke JF,Dinan TG,Kiely B,Shanahan F,Quigley EM.Bifidobacterium infantis35624 modulates host inflammatory processes beyond the gut.Gut Microbes 2013;4:325-339[PMID:23842110 DOI:10 .4161/gmic.25487]
145 Lin HC,Su BH,Chen AC,Lin TW,Tsai CH,Yeh TF,Oh W.Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.Pediatrics2005;115:1-4[PMID:15629973]
146 Bin-Nun A,Bromiker R,Wilschanski M,Kaplan M,Rudensky B,Caplan M,Hammerman C.Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.J Pediatr 2005;147:192-196[PMID:16126048]
147 Miele E,Pascarella F,Giannetti E,Quaglietta L,Baldassano RN,Staiano A.Effect of a probiotic preparation(VSL#3)on induction and maintenance of remission in children with ulcerative colitis.Am J Gastroenterol 2009;104:437-443[PMID:19174792 DOI:10.1038/ajg.2008.118]
148 Guandalini S,MagazzùG,Chiaro A,La Balestra V,Di Nardo G,Gopalan S,Sibal A,Romano C,Canani RB,Lionetti P,Setty M.VSL#3 improves symptoms in children with irritable bowel syndrome:a multicenter,randomized,placebo-controlled,double-blind,crossover study.J Pediatr Gastroenterol Nutr 2010;51:24-30[PMID:20453678 DOI:10 .1097/MPG.0b013e3181ca4d95]
149 Sood A,Midha V,Makharia GK,Ahuja V,Singal D,Goswami P,Tandon RK.The probiotic preparation,VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.Clin Gastroenterol Hepatol 2009;7:1202-1209,1209.e1[PMID:19631292 DOI:10.1016/j.cgh.2009.07.016]
150 Tursi A,Brandimarte G,Papa A,Giglio A,Elisei W,Giorgetti GM,Forti G,Morini S,Hassan C,Pistoia MA,Modeo ME,Rodino’S,D’Amico T,Sebkova L,Sacca’N,Di Giulio E,Luzza F,Imeneo M,Larussa T,Di Rosa S,Annese V,Danese S,Gasbarrini A.Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment:a double-blind,randomized,placebo-controlled study.Am J Gastroenterol 2010;105:2218-2227[PMID:20517305 DOI:10.1038/ajg.2010.218]
151 Gionchetti P,Rizzello F,Helwig U,Venturi A,Lammers KM,Brigidi P,Vitali B,Poggioli G,Miglioli M,Campieri M.Prophylaxis of pouchitis onset with probiotic therapy:a double-blind,placebo-controlled trial.Gastroenterology 2003;124 :1202-1209[PMID:12730861]
152 Mimura T,Rizzello F,Helwig U,Poggioli G,Schreiber S,Talbot IC,Nicholls RJ,Gionchetti P,Campieri M,Kamm MA.Once daily high dose probiotic therapy(VSL#3)for maintaining remission in recurrent or refractory pouchitis.Gut 2004;53:108-114[PMID:14684584]
153 Pronio A,Montesani C,Butteroni C,Vecchione S,Mumolo G,Vestri A,Vitolo D,Boirivant M.Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.Inflamm Bowel Dis 2008;14:662-668[PMID:18240282DOI:10.1002/ibd.20369]
154 Selinger CP,Bell A,Cairns A,Lockett M,Sebastian S,Haslam N.Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind,randomized,placebo-controlled clinical trial.J Hosp Infect 2013;84:159-165[PMID:23618760DOI:10.1016/j.jhin.2013.02.019]
155 van der Aa LB,van Aalderen WM,Heymans HS,Henk Sillevis Smitt J,Nauta AJ,Knippels LM,Ben Amor K,Sprikkelman AB.Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis.Allergy 2011;66:170-177[PMID:20560907 DOI:10.1111/j.1398-9995.2010.02416.x]
156 Perrin Y,Nutten S,Audran R,Berger B,Bibiloni R,Wassenberg J,Barbier N,Aubert V,Moulin J,Singh A,Magliola C,Mercenier A,Spertini F.Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461in patients with allergic rhinitis.Clin Transl Allergy 2014;4:1[PMID:24393277 DOI:10.1186/2045-7022-4-1]
157 Singh A,Hacini-Rachinel F,Gosoniu ML,Bourdeau T,Holvoet S,Doucet-Ladeveze R,Beaumont M,Mercenier A,Nutten S.Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen:an exploratory,randomized,placebo-controlled clinical trial.Eur J Clin Nutr 2013;67:161 -167[PMID:23299716 DOI:10.1038/ejcn.2012.197]
158 Xiao JZ,Kondo S,Yanagisawa N,Takahashi N,Odamaki T,Iwabuchi N,Iwatsuki K,Kokubo S,Togashi H,Enomoto K,Enomoto T.Effect of probiotic Bifidobacterium longum BB536[corrected]in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season.A randomized double-blind,placebo-controlled trial.J Investig Allergol Clin Immunol 2006;16 :86-93[PMID:16689181]
159 Odamaki T,Xiao JZ,Iwabuchi N,Sakamoto M,Takahashi N,Kondo S,Miyaji K,Iwatsuki K,Togashi H,Enomoto T,Benno Y.Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season.J Med Microbiol 2007;56:1301-1308[PMID:17893165]
160 Ouwehand AC,Nermes M,Collado MC,Rautonen N,Salminen S,Isolauri E.Specific probiotics alleviate allergic rhinitis during the birch pollen season.World J Gastroenterol2009;15:3261-3268[PMID:19598302]